Hartwick in SSTP Press Release
"'When I was approached to review the SSTP process and the utilization of the proprietary catalyst, I spent nearly five weeks reviewing the technical data before I agreed to accept the position as scientific and technical advisor. Only after I became convinced that the technology was based on sound scientific principles would I accept this position,' stated Dr. Thomas Hartwick." ~ Sustainable Power Corp. Appoints Dr. Thomas S. Hartwick as Scientific and Technical Advisor to the Company Dec 14, 2009
SSTP's John Rivera, in Federal Court
"The central fraud alleged involves claims by Rivera that USSE could produce viable commercial biofuel and fertilizer products." (Page 2.) (USSE = US Sustainable Energy Corp.)
"Rivera was also the principal shareholder of SSTP. According to the Commission, Rivera used SSTP for misconduct similar to that alleged in this case." (Page 3, Note 2)(SSTP = Sustainable Power Corp)
"The defendants also argue that two purported contracts filed with their response demonstrate that USSE (or, later, SSTP) was commercially viable." (Page 20)
~ Summary Judgment against John Rivera in July 2011, (Case 5:08-cv-00245-DCB-JMR) An exhibit in the case included the same Texas A&M study that Dr. Hartwick was tasked with. That report was submitted as an exhibit
We're talking about the original inventors of Clearsign's technology, not peripheral staff. Look up the Chief Science Officer David Goodson. Look up the lead inventor on Clearsign's first expressions of its technology: Thomas Hartwick.
Look up the numerous patents already in existence for this technology and you will see that any patents that CLIR scores will be very limited in scope.
Just go to Google patent search and look at the patent applications. Key inventors are David Goodson and Thomas Hartwick.
Also go to official web site of clearsign. David Goodson is listed as Chief Sci Officer. He is still claimed to have collaborated with nobel prize winners!
Buyer beware ... do a simple Google search on the Chief Science Officer and "original inventor" at Clearsign: David Goodson.
I only present the facts as found at the SEC, court system, US Patent office and others.
buyer beware. Do a simple Google search for the original inventors of Clearsign Combustion, esp. Chief Science Officer David Goodson and lead inventor on patents, Thomas Hartwick
Informed rational conclusions are positive ... not a downer. Uninformed rational decisions are the most dangerous decisions of all... and in all events, an inaccurate conclusion is not a positive, but a negative.
Buyer beware ... study Clearsign Combustion before you invest.
Phony patent claims
phony commercialization claims
... there is even a claim that he once collaborated with Nobel Prize winners .... before they became famous and while the two prize winners were living in separate countries.
He is also a key inventor on CLIR patents.
CLIR Chief Science Officer is David Goodson. Look him up.
Would like to know how everyone first heard of Clearsign? ... and How many are aware of the histories of the original inventors of Clearsign's technology?
Dr. Hartwick is a key inventor for CLIR's tech. He was also involved with SSTP -- whose CEO (John Rivera) ran a pump and dump scheme and was recently convicted of fraud in federal court. In the trial tech claims were debunked. Now Hartwick is on the CLIR team and is listed as an inventor on CLIR patents. Look him up, look up SSTP and John Rivera.
Virtually identical titles ... Syntax and word choice too close for individual thinking. Most likely very little, if any, research was done here. This reads like promotional language from Clearsign itself.
Sentiment: Strong Sell
Someone explain this to me. Here are the two virtually identical titles from two supposedly different journals.
Scientific American "Flame-Taming Electric Fields Could Make Power Plants Cleaner"
MIT Technology Review "Flame-Shaping Electric Fields Could Make Power Plants Cleaner"
"Much of the air pollution produced by today’s fossil-fuel power plants is the result of imperfect combustion. Hot spots in a flame increase the reactions between fuel and air molecules and lead to formation of common air pollutants like nitrogen oxides (or NOx, a precursor to smog), carbon monoxide (CO) and particulate matter."
MIT Technology Review:
"Much of the pollution from a power plant is the result of problems with combustion. If parts of a flame get too hot, it can lead to the formation of nitrogen oxides, which contribute to smog. Similarly, incomplete burning, which can result from the poor mixing of fuel and air, can form soot."
It is unclear to me whether or not Scientific American borrowed from the earlier MIT Technology Review, or whether both borrowed from some other text (like a company press release, presentation, or a rote telephone pitch). It is highly improbable however that both reporters independently researched the company and independently came up with the same title and much of the same message.
On the other hand, it is highly probable that the reporters were just saving time by working with management-prepared material. The “articles” read like promotional material designed by and for Clearsign, and not at all like independent research focused on the underlying technology and the original innovators.
"An open letter to Scientific American and MIT Technology Review"
Matt - 3 foot crowbar
Sentiment: Strong Sell
Doing your own DD is far superior to following sell-side analysts. Reading the 10-K at the SEC is a must.
Read the disclosures on analysts reports and see who is paying them. Also go to brokercheck at finra org and look up the institution behind the report. Look for regulatory events for Deutsche Bank Securities.
Yeah: Nov. 13, 2013 "Deutsche Bank maintained a Buy rating on Aegerion Pharmaceuticals (NASDAQ: AEGR) and raised its price target to $115.00 (from $107.00). Analyst Robyn Karnauskas sees accelerating sales."
"Following the Aegerion analyst day and our recent channel checks we are increasing our 2014 sales estimates and raising our TP to $115," said Karnauskas. "Given more docs are prescribing and scripts from current docs are increasing, we expect sales to continue to accelerate."
stock flew up to the 80's then crashed back into the 60's.
brokercheck at finra org shows a history for Deutsche Bank Securities. Almost 200 regulatory events, many involving research reports.
Sentiment: Strong Sell
could be more than 300 total US HoFH patients, but the number will be closer to 300 than 3,000. Subtract out the competition, drug interactions, and those who cannot tolerate Juxtapid and we'll find that AEGR's actual share is pretty small.
ISIS' Kynamro, ongoing anti-PCSK9 trials, gastrointestinal problems & fatty liver disease dropouts, statin interaction, exclusion of those under 18 yrs old, high cost, etc... will carve up AEGR's very very small pie into a very small slice. Note that besides the threat of anti-PCSK9 approval, the anti-PCSK TRIALS alone threaten AEGR market share ... and AMGN is recruiting as we speak.
"Amgen (AMGN) today announced that the Phase 3 MENDEL-2 (Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2) trial with evolocumab met its co-primary endpoints: the percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at week 12 and the mean percent reduction from baseline in LDL-C at weeks 10 and 12."
The study includes HoFH patients from AEGR's market.
"The Phase 3 studies will evaluate evolocumab administered every two weeks and monthly in multiple patient populations, including in combination with statins in patients with ...[other populations mentioned here, ending with] ... homozygous (TESLA and TAUSSIG) familial hypercholesterolemia."
Prevalence rate for the disease is 1 in one million. Approx. 300 HoFH patients in the USA.
Stock is grossly overvalued. Look at revenue versus market cap.
AEGR’s management is claiming a 3,000 patient population for the USA; the very scientists associated with its drug have said that there are about 300. Even a Nobel Prize winner used a prevalence rate that comes out to 300 US patients for HoFH.